| dc.description.abstract | Background: Multi drug resistant tuberculosis (MDR TB) is a condition in
which TB germs are resistant to isoniazid and rifampicin, the first line TB drugs.
MDR TB patients are then treated with second line drugs, including cycloserine.
Cycloserine treatment may cause depression. Various factors can increase
person's risk of depression, including age, gender, occupation, education, BMI,
comorbidities, and length of treatment. The purpose of this study was to determine
what factors can affect the level of depression due to the use of cycloserine in
MDR TB patients at dr. Soebandi Hospital. Method: The method used was
observational analytic with a cross-sectional approach. The population was all
MDR TB patients in dr. Soebandi Hospital in 2022-2024. Samples were taken
with the accidental sampling technique of as many as 89 patients. The primary
data was obtained from the Depression Anxiety Stress Scales (DASS 42)
questionnaire, and secondary data was obtained from medical records. Data
analysis was done using the chi-square test, and then the multivariate analysis
was continued using ordinal logistic regression. Result: The bivariate test results
showed that the variables that significantly influenced the level of depression
were gender (p=0.011), education (p=0.000), occupation (p=0.037), BMI
(p=0.000), and comorbidities (p=0.029). Multivariate tests showed that there
were three variables that had a significant effect (p-value <0.05) on the level of
depression, namely gender (p=0.047), occupation (p=0.001), and comorbidities
(p=0.011). The top two dominant risk factors affecting the level of depression are
occupation (OR=17,12) and comorbidities (OR=9,14). Conclusion: Based on
these results, it can be concluded that the risk factors that influence the level of
depression in MDR TB patients receiving cycloserine therapy are gender,
education, occupation, body mass index (BMI), and comorbidities. The risk
factors that most influence the level of depression are occupation and
comorbidities. | en_US |
